Albus Health
Founded 2017 Β· 8 employees on LinkedIn Β· 4 known investors
Albus Health develops clinically validated monitoring technology that tracks respiratory metrics, heart rate, and cough frequency to support clinical studies. Its team includes clinicians, respiratory and sleep researchers, biomedical engineers, and computer scientists serving the clinical research and medical technology field.
Also known as Albus Health Ltd
Founders & leadership
Investors Β· 4
Company profile
researched Aug 2026Albus Health is a UK company that develops contactless remote patient monitoring technology for clinical trials and academic research. Its product, Albus Home, is a compact device placed on a bedside table that passively records clinically relevant signs overnight without participants needing to wear or operate anything. Measured parameters include respiratory rate, heart rate, cough frequency, laboured breathing, sleep, and environmental metrics such as air particulate matter, humidity and temperature, with more than 12 parameters captured by a single device.
The company positions the device as an end-to-end solution for traditional, decentralised and hybrid clinical trials, supporting participant compliance and streamlined data collection for pharmaceutical sponsors and clinical researchers across multiple therapeutic areas. It also partners with academic groups to develop novel digital biomarkers and generate disease and treatment insights. The team combines clinicians, respiratory medicine and sleep researchers, biomedical engineers, computer scientists and med-tech business leaders; named roles include CEO and co-founder Mikesh Udani, Medical Director Dr. William Do, CTO Jose Sanchez, clinical leads Prof Mona Bafadhel, Dr Richard Russell and Prof Ian Pavord, Head of R&D Prof Maarten De Vos, and non-executive director Colin Reisner.
Founding story
Albus Health originated as an Oxford University spin-out. According to co-founder and CEO Mikesh Udani, while working as researchers at the university the founders found that monitoring night-time symptoms at home was a significant unmet challenge, contributing to preventable emergencies and inefficiencies in clinical studies. To address this they built a small contactless bedside device that automatically monitors a range of symptoms and air quality metrics without any action required from the patient. The company was started in 2017, following a few months of prior work on the technology.
Business model
Albus Health supplies its contactless monitoring device and associated data collection service to pharmaceutical companies and clinical research organisations running clinical trials, and partners with academic researchers on studies and digital biomarker development. Engagements described include commercial device supply contracts, collaborative clinical study contracts, and the company's own market access studies.
Commercial contracts for the supply of Albus Home devices and end-to-end monitoring services to clinical trial sponsors and research collaborators.
Traction
The company reports 5 billion data points recorded across global trials, more than 12 parameters captured per device, and certification in over 40 countries including CE, FCC and UKCA marks. Its product is used in commercial and collaborative clinical studies across respiratory conditions; as of early 2023 this included work with a major pharmaceutical company and an imminent 120-child paediatric asthma study commissioned by the Department of Health.
Latest developments
Announced expansion of availability across Latin America, Asia-Pacific and the Middle East to enable standardised data collection in multinational clinical trials, and published material on continuous night-time symptom monitoring in clinical practice. Earlier developments include the detection of early warning signs of child asthma attacks up to five days before onset and participation in the AstraZeneca BioventureHub and UCB Digital Care Transformation Incubator.
βΈFull profile β market position, technology, go-to-market, geography, history
Market position
Positions itself as an end-to-end contactless nocturnal monitoring solution for clinical trials, aiming to become a standard for nocturnal symptom monitoring; the company states it works with world-leading pharmaceutical companies and clinical researchers.
Monitoring requires no wearable or daily patient action β participants plug the device in and leave it β which study participants and research nurses quoted by the company contrast favourably with other study devices requiring daily tasks or extensive training. A single compact device captures more than 12 physiological and environmental parameters, with published validation against polygraphy, ECG and human cough labelling.
Technology
Albus Home is a compact, contactless bedside device that passively and continuously monitors clinical signs overnight without contact or wearables. It captures respiratory rate, heart rate, cough frequency, laboured breathing, sleep and air quality metrics including particulate matter, humidity and temperature β more than 12 parameters in one unit. The company reports validation figures of 98%/98.3% accuracy for respiratory monitoring versus gold-standard polygraphy, 92% accuracy for heart rate versus 3-lead ECG/EKG, and an intraclass correlation coefficient of 0.99 for cough frequency against ERS-defined human cough labels. The company also cites an application in detecting early warning signs of child asthma attacks up to five days before onset.
Go-to-market
Direct engagement with pharmaceutical sponsors and clinical research teams for trial deployments, supported by academic research partnerships, demo requests through the website, and participation in pharmaceutical innovation programmes such as AstraZeneca's BioventureHub and the UCB Digital Care Transformation Incubator.
Pharmaceutical companies running clinical trials, contract and academic clinical researchers, hospitals, clinics, research institutions and government bodies.
Geography
Headquartered in Oxford, United Kingdom, with devices certified in more than 40 countries and announced availability across Latin America, Asia-Pacific and the Middle East for multinational clinical trials.
History
The company was founded in 2017 as an Oxford spin-out and received its first external investment in its early days. By early 2023, roughly four years into operations, the product had been commercially launched and was in use in both commercial and collaborative clinical studies, including work with one of the world's largest pharmaceutical companies, which invited Albus to set up an office at its R&D headquarters. A Department of Health-commissioned study of 120 children with asthma, run with paediatric respiratory opinion leaders in London and Birmingham, was described as about to begin. In May 2024 the company joined AstraZeneca's BioventureHub and the UCB Digital Care Transformation Incubator, where it won the Jury Prize. In November 2024 it reported that its device detects early warning signs of childhood asthma attacks up to five days before onset, and in May 2026 it announced availability across Latin America, Asia-Pacific and the Middle East.
Compiled by commissioned research from 7 cited public sources β announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Timeline Β· 6
launches, deals, and filingsAnnounced global footprint expansion enabling standardised data collection in multinational clinical trials.
CEO Mikesh Udani stated in a January 2023 interview that the product had been launched commercially earlier that year and was in use by multiple parties, including one of the largest pharmaceutical companies in the world.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
βΈResearch sources Β· 7
primary sources listed
- Albus Healthalbushealth.com Β· web
7 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Albus Health do?
- Oxford University spin-out making a contactless bedside device that monitors sleep, vital signs and cough for clinical trials.
- Who are Albus Health's investors?
- Albus Health's investors include Creative Destruction Lab (CDL), Meridian Health Ventures, Parkwalk Advisors, UCeed Funds.